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Abstract 
Historically, research and development (R&D) in the pharmaceutical sector has predominantly been an in-house 
activity. To enable investments for game changing late-stage assets and to enable better and less costly go/no-go 
decisions, most companies have employed a fail early paradigm through the implementation of clinical proof-of-con-
cept organizations. To fuel their pipelines, some pioneers started to complement their internal R&D efforts through 
collaborations as early as the 1990s. In recent years, multiple extrinsic and intrinsic factors induced an opening for 
external sources of innovation and resulted in new models for open innovation, such as open sourcing, crowdsourc-
ing, public–private partnerships, innovations centres, and the virtualization of R&D. Three factors seem to determine 
the breadth and depth regarding how companies approach external innovation: (1) the company’s legacy, (2) the 
company’s willingness and ability to take risks and (3) the company’s need to control IP and competitors. In addition, 
these factors often constitute the major hurdles to effectively leveraging external opportunities and assets. Conscious 
and differential choices of the R&D and business models for different companies and different divisions in the same 
company seem to best allow a company to fully exploit the potential of both internal and external innovations.
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Background
Traditionally, pharma R&D organizations are fully inte-
grated; they are composed of various units with different 
competencies, skills and technologies and have complex 
interfaces to accomplish the multi-disciplinary tasks 
required for developing new drugs. Regulatory hurdles, 
complex research for new drug targets, or the low pre-
dictability of animal models are some examples of why 
the industry is struggling with its R&D input/output-
ratio [1, 2]. These internal and external challenges made 
it necessary for companies to improve their R&D efficien-
cies, e.g. by outsourcing to reduce overhead costs, by the 
installation of proof-of-concept (PoC) organizations or 
by enhanced scientific rigor in data-driven project deci-
sion-making. The latter is included today in many (if not 
most) decisions that take into account the probability of 
technical success (PoS), the likelihood of achieving the 
target product profile (TPP) and the resources needed 
to achieve the TPP. The translation of innovations from 
research into clinically meaningful therapies for patients 
has become the key value generating step in pharmaceu-
tical R&D. Nonetheless, in view of the high complexity 
of clinical PoC, the attrition rate in the PoC phase is still 
the highest. This raises the question regarding whether 
a decentralized and more open R&D organization that 
accesses additional competencies, skills and technologies 
from external sources could be a measure to increase the 
R&D efficiency.
Generally, a centralized R&D approach is particularly 
favoured and relevant in disease areas that necessitate 
large and long clinical trials to demonstrate PoC and 
where deep developmental, regulatory and commer-
cial expertise is essential. Whenever an R&D activity is 
more singular and autonomous or as soon as less synergy 
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within a portfolio of R&D projects exist, a decentralized 
R&D may have advantages over a central R&D organiza-
tion since the company has the opportunity to copy the 
science-based biotech business model. Hence,  pharma 
companies have increasingly moved away from internal 
R&D models towards more open and collaborative R&D 
models following the paradigm of open innovation [3]. 
In this vein, they have established specific collaborations 
with academic centres of excellence, built innovation 
centres, made joint ventures with academic institutions 
(public–private partnerships, PPP), established precom-
petitive consortia, or experimented with crowdsourcing 
and virtual R&D [4–7]. Some models even let com-
petitors collaborate and become partners [8]. Currently, 
many companies have put greater focus on leveraging 
external knowledge, licensing or acquiring drug candi-
dates and changing their R&D models from primarily 
inside-driven concepts to plans that more closely follow 
the open innovation paradigm [4]. As a consequence, 
the proportion of externally sourced R&D assets has 
increased in the past years [9]. This rise in externally 
sourced innovation coincided with several cases of major 
downsizing in R&D departments, with Merck, AstraZen-
eca and Pfizer being the biggest proponents of the R&D 
cuts [10–14].
This paper summarizes the current situation of open 
innovation in the pharmaceutical sector. It describes the 
concepts and models of opening up pharma R&D, and 
it attempts to address the questions regarding why big 
pharma has not yet fully embraced the different ideas 
of open innovation and what measures would help to 
increase R&D productivity and efficiency.
Open source and crowdsourcing to access 
knowledge of the masses
Open source innovation has been successfully applied in 
the software industry. This radical open model of soft-
ware development allows anyone to participate, network 
in the product’s development and then share the results. 
Rewards for participants are mostly non-monetary but 
are related to recognition and participation, such as the 
presentation of expertise, the satisfaction by working 
on an honourable project, the acquisition of new skills, 
or peer recognition. Around the time when internet 
became a commodity, the players in the pharmaceuti-
cal sector became more connected, and in turn, it was 
possible for R&D organizations to become more decen-
tralized. This development allowed pharmaceutical com-
panies to more easily access knowledge and ideas from 
the outside, promote innovation, use the mass of external 
experts to solve problems and to develop technologies 
through collaborative improvements [15, 16]. For exam-
ple, the Human Genome Project has been a pioneering 
open source activity in the biomedical environment [17]. 
In addition, open-access scientific journals follow the 
principle of the free distribution of scientific informa-
tion and knowledge. Other examples that are known are 
from non-profit organizations and governments to dis-
cover drugs for neglected diseases in collaboration with 
pharma companies [18]:
  • In 1974, the Special Program for Research and Train-
ing in Tropical Diseases (TDR, http://www.who.int/
tdr/en/) was initiated by the World Health Organi-
zation (WHO) as a global programme of scientific 
collaboration to combat neglected diseases [18]. The 
programme is hosted at the WHO and funded by 
co-sponsors, governments, foundations and agen-
cies, such as the World Bank, the European Com-
mission, or the Bill and Melinda Gates Foundation 
[19]. The African Network for Drugs and Diagnostics 
Innovation (ANDI) is a programme of the TDR that 
started in 2008 under the governance of the United 
Nations Economic Commission for Africa (UNECA). 
It focuses on the specific health needs in Africa and 
aims at promoting and supporting pharmaceutical 
R&D for neglected diseases led by African institu-
tions to develop capacities and centres of research 
excellence there [20].
  • The Medicines for Malaria Venture (MMV, https 
://www.mmv.org) was established in 1999 by a few 
European governments together with the World 
Bank to reduce the disease burden of Malaria infec-
tions [21]. Since then, the programme has gained 
more facilitators and received total funding of 
roughly USD 1 billion by 2016. The main sponsor is 
the Bill and Melinda Gates Foundation, with a 54.7% 
share. Partners form the industry include Novartis, 
Sanofi, Merck Serono and Takeda. The achievements 
are enormous. Several hundred million treatments 
were provided to children; 18,000 healthcare workers 
were trained to administer malaria medication; and 
19 drug candidates have been nominated for clini-
cal development since 1999. Since 2010, the MMV 
moved 17 candidates into preclinical development, of 
which 13 are still active [74].
  • The Global Alliance for Tuberculosis Drug Develop-
ment (TB Alliance, https ://www.tball iance .org) is 
an initiative of governmental and non-governmen-
tal organizations. It was started in 2000 to discover 
and develop tuberculosis drugs. Today, the TB Alli-
ance manages the largest pipeline of new TB drugs, 
including six new products that are in clinical devel-
opment phases. Several pharmaceutical companies, 
such as Sanofi, Bayer or GSK have entered into col-
laborations with TB alliance in the past, whereas 
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more recently Novartis transferred an entire R&D 
program to the TB alliance [71].
  • A further open source example is the Drugs for 
Neglected Diseases Initiative (DNDi, https ://www.
dndi.org) that is supported and sponsored by numer-
ous universities, research centres, governmental 
organizations, biotech companies, and several phar-
maceutical companies, such as AstraZeneca, Bayer 
Healthcare, Bristol-Meyers Squibb (BMS), Genom-
ics Institute of the Novartis Research Foundation, 
GSK, Pfizer, Sanofi and Takeda. It provides platforms 
for collaborative non-for-profit drug discoveries and 
developments for diseases such as Leishmaniasis, 
Sleeping Sickness, Chagas disease and paediatric 
HIV. Since 2003, DNDi developed four new drugs 
for the treatment of neglected diseases and plans 
to deliver 16-18 total new treatments with a total 
budget of EUR 650 million by 2023.
  • Open source drug discovery (OSDD) was initiated 
by the Indian government in 2008 as a translational 
platform for drug discovery [22]. The hybrid model of 
open source and public private partnership brought 
together companies, organizations and scientists 
from different industries (such as TCG Lifesciences, 
Sun Microsystems, the Institute of Genomics and the 
Integrative Biology or Sky Quest Labs) in order to 
establish high-quality research on neglected diseases 
(such as tuberculosis) at low costs [69]. In its Con-
nect to Decode initiative, the 4000 genes of Mycobac-
terium tuberculosis were annotated, and a metabo-
lome and a protein–protein functional network of 
this germ were delivered [69]. OSDD also provides 
data on promising exploratory tuberculosis drugs 
via its website (http://www.osdd.net/home) and sup-
ports the progress of drug discovery projects [70].
  • Finally, the Pool for Open Innovation started in 
2009 as a partnership of GSK, Alnylam Pharmaceu-
ticals and the Massachusetts Institute of Technology 
(MIT). It provides free access to 2300 tropical dis-
ease patents and ensures that these intellectual prop-
erty (IP) rights do not hinder drug discoveries on 
neglected diseases.
These examples show how open sourcing in the 
pharma sector is being used to make drug development 
for neglected diseases feasible, thus ensuring afford-
able drugs for those who need them [18]. In addition, it 
reflects the important social function that the pharma-
ceutical industry has to play in developing new medica-
tions in financially unattractive markets. However, this 
does not perfectly fit with the pharmaceutical business 
model, which is built on large R&D investments, confi-
dentiality, proprietary IP and returns-on-investment, and 
does not serve the needs of the industry to increase pro-
ductivity in its core businesses [23].
Crowdsourcing is “a form of sourcing in which individu-
als or organizations solicit contributions from Internet 
users to obtain desired services or ideas” and has been 
described as a new business practice [24, 25]. Like open 
sourcing, crowdsourcing uses the mass of worldwide 
experts to get problems solved. Companies act as seekers 
and brokers. They post their questions or issues to a large, 
company-unknown, diverse group of experts and invite 
them to provide solutions. The external experts who are 
the solvers tackle the problems in return for financial 
gratification. Mining crowd data, web search logs, smart 
phone applications, social media, and active crowdsourc-
ing are types of crowdsourcing that have found their way 
into the pharmaceutical business [26].
Active crowdsourcing is a cost-efficient way of open 
innovation that goes far beyond the more traditional 
models of research collaborations and partnerships [27–
30]. The advantages include:
  • The integration of external knowledge,
  • The access to new technologies,
  • The solving of problems that could not have been 
solved by internal experts, and
  • A reduction of overhead costs.
The formal hurdles to implement successful active 
crowdsourcing are relatively low. The initiative needs to 
be publicized properly, the submission process needs to 
be simple and non-bureaucratic, and questions and chal-
lenges need to be precisely defined [31]. Hence, it is of 
great surprise that most of the big pharmaceutical com-
panies apply only a seeker-like approach to get single 
problems solved by collaborating with platform providers 
(such as Innocentive) rather than hedging the full poten-
tial of crowdsourcing (Table 1).
So far, only Eli Lilly, Bayer Healthcare and AstraZeneca 
run their own crowdsourcing platforms:
  • Eli Lilly left an early mark with Innocentive (2001), 
YourEncore (2003), and Open Innovation Drug Dis-
covery (https ://openi nnova tion.lilly .com/dd/) [32].
  • AstraZeneca runs an open innovation platform 
(https ://openi nnova tion.astra zenec a.com) that pro-
vides access to innovative discovery technologies.
  • And Bayer HealthCare initiated Grants4Targets 
(G4T) (2009) [33, 34], Grants4Leads (2014; http://
www.grant s4lea ds.com), and Grants4Apps (2013, 
https ://www.grant s4app s.com). G4T is an open inno-
vation platform to access new drug discovery ideas to 
fill Bayer Healthcare’s R&D pipeline. The process is 
simple and fast. External scientists are invited twice a 
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year to propose their ideas for targets and an animal 
model. The administrative hurdles are low since the 
IP stays with the inventor. The proposals are evalu-
ated by Bayer scientists, and if a proposal is accepted, 
the proposer receives a financial reward. If a proposal 
results in a project that finds its way officially into 
Bayer’s drug pipeline, then both parties can negotiate 
a collaborative agreement. So far, G4T has been very 
successful, as indicated by more than 1100 applica-
tions and inputs into 10 drug discovery projects that 
have led to 6 lead generations, 1 lead optimization 
and 2 drug development projects [34].
Other examples regarding how crowdsourcing is used 
by pharmaceutical companies are as follows:
  • Novartis partnered with PatientsLikeMe (http://
www.patie ntsli keme.com) [35], a digital health learn-
ing system comprising more than 600,000 partici-
pants’ health conditions.
  • Novartis also uses the digital trial technology of Sci-
ence 37 to allow patients an easy participation in 
clinical trials and to move more and more to a site-
less trial model.
  • A recent new partnership of Novartis is the one with 
Pear Therapeutics on a digital therapeutic called 
THRIVE [72].
  • Merck & Co. collaborated with Kaggle (http://www.
kaggl e.com) [36] to identify statistical techniques for 
predicting the biological activities of different mol-
ecules.
  • Sanofi has applied a more focused approach around 
Diabetes using the Data Design Diabetes Innova-
tion Challenge to seek service solutions for diabetes 
patients.
  • GSK uses crowd sourced data and its Flumoji app to 
identify the fluctuations of flu infections [37].
  • And BioMedX (https ://bio.mx/) is an example of 
a new open innovation model at the interface of 
crowdsourcing and innovation centres that includes 
pharma companies, such AbbVie, Boehringer Ingel-
heim, Johnson & Johnson (J&J) or Merck and aca-
demia. Physically based on the campus of Heidelberg 
University, experts from universities and pharma 
partners support the interdisciplinary projects of 
teams of young scientists. Anyone (the crowd of 
scientists) can apply via the internet and can ask for 
financial and scientific support to study new drug 
discovery ideas in the biomedical field (oncology, 
respiratory diseases, neuroscience, diagnostics and 
consumer care) with the purpose of translating the 
research activities into drug development projects of 
the respective pharma partner.
Public private partnerships to improve competitiveness
PPPs have emerged as another cost-efficient way to pro-
pel drug innovations [38, 39]. These business ventures are 
financed and operated by a partnership of academic or 
publicly funded institutions, charities [such as the Bill & 
Melinda Gates Foundation (http://www.gates found ation 
.org)], and pharmaceutical companies. PPPs contribute 
to drug discovery efforts and allocate their resources 
primarily in niche indications with high unmet medical 
needs in which pharma companies are traditionally less 
active. In these open networks, the participants exchange 
data, bring in their expertise, resources and IP, and 
Table 1 Examples of crowdsourcing in the pharma industry
Type of crowdsourcing Example Owner Topics
Mining crowd data Open FDA FDA Access to publicly available FDA data
Web search logs Google trends Google Statistical analyses on health topics
Smart phone applications Flumoji GSK Track flu outbreaks
Active crowdsourcing (pharma-
specific platform)
Grants4Apps Bayer Electronic health
Grants4Leads Bayer Drug discovery in animal health
Grants4Targets Bayer Target proposals
Open innovation drug discovery Eli Lilly Drug discovery
Molecular modelling
In vitro screening
Drug discovery in animal health
Compound proposals and synthesis
NTD research
Open innovation platform AstraZeneca Drug discovery
Target proposals
Data mining
Chemoinformatics
Preclinical and clinical translational research
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consequentially leverage synergies and share risk. So far, 
there are numerous convincing examples demonstrating 
the potential of PPPs in the pharmaceutical sector [40]. 
Amongst them, the most prominent are as follows:
  • The Biomarker Consortium (source: http://www.
bioma rkerc onsor tium.org),
  • The Critical Path Institute Consortia (www.c-path.
org/conso rtia.cfm),
  • The Innovative Medicine Initiative (www.imi.europ 
e.eu),
  • The Serious Adverse Events Consortium (http://
www.saeco nsort ium.org),
  • The National Center for Advanced Translational Sci-
ences (https ://ncats .nih.gov),
  • Bristol–Myers Squibb’s International Immuno-
Oncology Network (http://www.immun oonco logyh 
cp.bmsin forma tion.com),
  • The Global Alliance for Vaccines and Immunizations 
(http://www.gavi.org),
  • The Global Fund to Fight AIDS, Tuberculosis and 
Malaria (http://www.thegl obalf und.org/),
  • The Stop TB Partnership (http://www.stopt b.org),
  • Roll Back Malaria (http://www.rollb ackma laria .org), 
and
  • The FDA initiated the Critical Path Initiative [41].
More specifically, the Innovative Medicines Initiative 
(IMI) is a PPP established by the European Union (EU) 
and the European Federation of Pharmaceutical Indus-
tries and Associations (EFPIA) [42, 43]. Its goal is to 
accelerate the development of better and safer medicines. 
IMI has been engaged in the areas of establishing robust 
and validated models for drug development, eliminating 
poorly predictive preclinical models, providing novel bio-
markers and drug targets, and establishing more effec-
tive tools and methods to predict adverse drug effects 
[44, 45]. With funding of up to EUR 5 billion, the IMI is 
stocked to boost the development of new medicines in 
Europe until 2024. Today, 86 consortia with 593 research 
teams of EFPIA members, 1214 teams of academic part-
ners and 249 other partner teams are supported by IMI. 
They focus on all kind of pharmaceutical research top-
ics, including infectious diseases (14%), CNS disorders 
(10%) or biomarkers (10%) (see Table 2). Sanofi, GSK, J&J 
and AstraZeneca are the most active contributors from 
the pharmaceutical industry. They use the potential of 
IMI intensively by contributing 51, 47, 46, and 44 teams 
to different projects, respectively (see Table 3). ADAPT-
Smart (17 pharma partners), EUPATI (13 pharma part-
ners), GETREAL (13 pharma partners) and PREFER (13 
pharma partners) are the projects that have the most 
EFPIA partner companies. They cover topics of medical 
research, clinical development (ADAPT-Smart, GET-
REAL, PREFER) and medical training (EUPATI). To give 
a few more examples:
  • The SAFE-T consortium (http://www.imi-safe-t.eu) 
has been initiated to identify biomarkers for the early 
detection of drug-related safety issues related to the 
kidney, liver and vascular systems [46].
  • The U-BIOPRED (http://www.europ eanlu ng.org/
en/proje cts-and-resea rch/proje cts/u-biopr ed/home) 
and the PRECISESADS (http://www.preci sesad s.eu) 
consortia are both active in the field of personalized 
medicine in order to address the need for the char-
acterization and classification of severe refractory 
asthma and autoimmune diseases [47, 48].
  • The Open Pharmacological Concepts Triple Store 
(Open PHACTS, http://www.imi.europ a.eu/conte 
nt/open-phact s) is another PPP with AstraZeneca, 
Eli Lilly, GSK, Merck, Novartis and Pfizer that com-
plements the 31 consortia members of universities, 
research organizations, public bodies and govern-
mental organizations. It aims at delivering an open 
pharmacological space and linking diverse and com-
plementary drug discovery databases to support drug 
research [49].
  • Most likely, the most prominent example of an IMI 
projects is the European Lead Factory (ELF) that 
aims at providing new drug targets for all kinds 
of disease areas [50]. Any scientist from a Euro-
pean academic institution or small- to medium-
sized entity (SME) can present a target proposal 
for High-Throughput-Screening (HTS) or ideas 
for a compound library. The ELF currently brings 
together 30 internal partners from private and pub-
lic organizations, including AstraZeneca, Bayer, 
Table 2 Overview of the IMI projects’ positioning
Source: http://www.imi.europ a.eu/proje cts-resul ts/proje ct-facts heets 
Topic Number of projects Ratio (%)
Biomarkers 9 10
Cancer 4 5
CNS disorders 11 13
Diabetes 3 3
Infectious diseases 12 14
Medical research and clinical devel-
opment
6 7
NTDs 6 7
Others 17 20
Pain 4 5
Toxicology and drug safety 5 6
Medical training 4 5
Vaccines 5 6
Total 86
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and Sanofi (https ://www.europ eanle adfac tory.eu/
about /partn ers/). Starting in 2013, IMI’s goal is to 
identify high quality small molecule drug candi-
dates. By 2017, the ELF had delivered 300,000 new 
chemical compounds that were combined with the 
300,000 compounds that have been provided by the 
EFPIA collection to a Joint European Compound 
Library of more than 500,000 chemical compounds 
for HTS screening. In addition, by end of 2015, 60 
drug target proposals had been evaluated positively 
and accepted, and more than 500 hits had been 
handed over to academic institutions and SMEs for 
further drug development.
The IMI consortia cover topics of high medical need 
and/or regulatory relevance (see Table  2). The projects 
generally address topics of the highest scientific and 
operational complexity that need a multi-stakeholder 
environment and that do not affect the business success 
of the participating companies directly. This open inno-
vation model improves companies’ competitiveness and 
thus may help reduce R&D costs. Meanwhile, it does not 
increase the competition amongst the companies. It helps 
reduce the fragmentation of knowledge that is inherent 
to the IP-driven pharma industry. Other projects of IMI 
also stimulate the interest of pharmaceutical companies 
in research topics that would not have been examined 
without rewards, such as antimicrobials (see ENABLE) or 
Ebola vaccines (see EBOVAC1).
In summary, pharmaceutical companies use PPPs as a 
tool of precompetitive collaboration with peers:
  • To increase scale,
  • To strengthen research networks,
  • To share risk with industry partners,
  • To integrate external (university) know-how,
  • To access public financial resources,
  • To accelerate the exploitation of innovation,
  • To serve society and increase reputation, and
  • To improve R&D productivity [51].
In addition, they need to meet the following challenges 
to leverage the potential of PPPs:
  • Pool and share the right data that are relevant for the 
PPPs,
  • Manage the alliances professionally,
  • Exclude the IP relevant (competitive) topics,
  • Manage the IP rights if such rights result from a PPP,
  • Manage the cultural conflicts of partners, and
  • Align the diverse interests of partners that are com-
ing from academia and industry.
Pharma innovation centres and research alliances 
to leverage synergies from open innovation
Another path to open up R&D and to access exter-
nal innovation is pharma innovation centres. They 
may be best described as hybrid models of centralized 
R&D mixed with elements of open innovation. Some 
of the biggest players in the pharmaceutical sector have 
embraced this new concept that brings scientist from 
pharmaceutical companies and experts from the aca-
demia together to solve problems, provide new solutions 
and deliver innovative products.
  • Pfizer started in 2010 their Global Centers for Thera-
peutic Innovation (CTIs), a USD 85 million partner-
ship with the University of California at San Fran-
cisco (UCSF). This one example out of eight planned 
CTIs shall become part of Pfizer’s BioTherapeutics 
Research Group and it is Pfizer’s way to leverage 
synergies from open innovation at the interface of 
translational research between Pfizer and academic 
medical centres (http://www.pfize rcti.com). The 
idea is that Pfizer adds its developmental knowledge, 
financial resources and human resources to the col-
laboration. Meanwhile, it expects to benefit from the 
research expertise in disease areas, target biology and 
patient populations from their academic partners. 
Partners in the CTI network include 25 academic 
Table 3 Overview of pharmaceutical companies contributing 
to IMI
Source: http://www.imi.europ a.eu/proje cts-resul ts/proje ct-facts heets 
Total number of teams 
active in IMI projects
Sanofi 51
GlaxoSmithKline 47
Johnson & Johnson 46
AstraZeneca 44
Novartis 36
Pfizer 34
Eli Lilly 32
Roche 31
Bayer 29
Boehringer Ingelheim 28
UCB 25
Novo Nordisk 21
Merck 20
Amgen 16
AbbVie 13
Merck & Co. 10
Takeda 7
BristolMyersSquibb 5
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institutions, four patient foundations, the National 
Institute of Health (NIH) and large hospitals such as 
the Medical Center at Columbia University, the Tufts 
Medical Center or Mount Sinai Hospital. Together 
with the NIH, Pfizer plans to identify new drugs that 
serve both partners’ strategic interests. NIH scientists 
provide more of the research aspects in the collabo-
ration (such as disease-related pathways or mecha-
nisms as potential drug targets), while Pfizer enables 
the NIH to move new drug projects into therapeutic 
development using industry-standard translational 
tools and Pfizer’s developmental expertise.
Other large pharma companies have also started their 
own innovation centres:
  • Bayer HealthCare, the German Cancer Research 
Center (DKFZ) and the National Center for Tumor 
Diseases (NCT) initiated a drug discovery alliance in 
2009 where DKFZ and NCT provide their expertise 
in cancer research and tumour biology, and Bayer 
brings in its know-how in drug R&D. The goal of this 
strategic partnership is technology transfer from the 
DKFZ to Bayer [52].
  • Bayer HealthCare recently opened a centre in San 
Francisco to identify and manage partnerships with 
academic and biotech researchers in the USA [53].
  • The German company Merck established a new 
innovation centre located at their headquarters to 
open Merck’s R&D towards innovation from the out-
side and to provide a platform for external innovation 
to translate their ideas into real business cases [54].
  • J&J started its Life Science Innovation centre in San 
Diego with a Concept Lab that provides a platform 
for start-up companies in the earliest phase and with 
the Open Collaboration Space that gives the start-
up companies desk space later in their development. 
With both programmes, J&J enables innovators to 
get an early proof-of-concept for their ideas by offer-
ing infrastructure, equipment and resources [55].
  • GSK experimented much earlier in the field of open 
innovation with the Center of Excellence for Exter-
nal Drug Discovery (CEEDD). At its start in 2005, 
CEEDD’s goal was to better access external tech-
nologies using a small team of approximately 20 
GSK scientists to work across all therapeutic areas 
and facilitate partnerships from drug discovery to 
PoC. Until its closure in 2012, CEEDD managed 
a total of 16 partnerships. One example for col-
laboration under this umbrella is the GSK alliance 
with ChemoCentryx, which was established in 
2011 to access the technology of chemokine-based 
therapeutics. After one of the trials failed and the 
chemokine receptor 9-inhibitor did not achieve 
its primary endpoint for the treatment of Crohn’s 
disease, the programme was discontinued. Despite 
such drawbacks, CEEDD was successful in estab-
lishing both the internal and the external paths to 
access drug candidates at GSK and it helped to fill 
GSK’s early stage pipeline currently covers nearly 
half of its projects that are externally sourced [56].
  • Since more than a decade Novartis and the MIT 
are collaborating on continuous manufactur-
ing (https ://novar tis-mit.mit.edu/). In 2018 they 
added a partnership with MIT’s Computer Science 
and Artificial Intelligence Laboratory (CSAIL) on 
patient real-time motion monitoring [73].
  • Novartis has also successfully collaborated with 
selected institutions such as the Dana–Farber Can-
cer Institute on cancer alliances or the University 
of Pennsylvania on the chimeric antigen receptor 
(CAR) T cell [57]. In a recent interview, Novartis 
Institutes for BioMedical Research’s (NIBR) presi-
dent Jay Bradner announced a division-wide pro-
gramme to enhance the external focus and foster 
external collaborations in several ways [58]. A fac-
ulty of scholars will be invited to join NIBR to lead 
their own projects that “would not be accessible in 
their home institutions” [58]. This could be access to 
technologies but also libraries of molecules to test 
new concepts. The programme is special and dif-
ferent from other open innovation models since it 
focuses on sourcing new ideas into a company and 
provides leading academic scientists and innovators 
the opportunity to benefit from pharma’s strengths. 
Thus, this turns the effort into a collaborative part-
nership to the benefit of science and patients.
  • In addition Novartis has started “Genesis labs” to 
offer employees the opportunity to suggest high-
risk, high-reward transformational projects and 
apply for resources, funding and lab space.
  • Another example of a pharma innovation centre is 
Takeda’s Center for IPS Cell Research Application 
(CiRA) at Kyoto University (TCiRA). Launched in 
2015, its goal is to investigate cell therapies for the 
treatment of cardiovascular, metabolic, neural and 
cancer diseases. While Takeda provides 10 years of 
funding of approximately US$ 177 million, research 
management expertise, Takeda researchers, access 
to its compound library and access to the research 
facilities at its Shonan Research Center in Japan, 
it can benefit from the world-class science of 
the CiRA team that is headed by director Shinya 
Yamanaka, the 2012 Nobel Prize winner on induced 
pluripotent stem (iPS) cells.
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  • Takeda is one of the global players that has reduced 
its internal R&D over the past years and that increas-
ingly uses the potential of external R&D [59, 60]. It 
recently announced a collaboration with the Tri-
Institutional Therapeutics Discovery Institute (TDI) 
in New York, which is a consortium of three institu-
tions (Cornell University, Rockefeller University, and 
Memorial Sloan Kettering Cancer Center), to sup-
port target research [61]. It also collaborates with J&J 
and OrbiMed Advisors LLC by co-investing in the 
Israeli biotech accelerator FutuRx with the purpose 
to fund medical breakthrough innovations that can 
be spun off in the form of new, independent compa-
nies [62].
These examples demonstrate how access to world-class 
science is facilitated by agreeing on a long-term partner-
ship with academic institutions. The further advantages 
of innovation centres are:
  • They bypass tedious long-lasting licensee-licensor 
negotiations in subsequent drug licensing;
  • They allow access to internal scientific resources 
within the remit of the arrangement, which is an 
important flexibility given the risks of pharmaceuti-
cal R&D;
  • They allow R&D to familiarize themselves with new 
technologies or therapeutic indications without the 
need to make significant investments upfront; and 
  • They give access to potential new drug candidates.
Conversely, the academic and biotechnology partners 
also benefit from such collaborations. They get access to 
the drug discovery, developmental expertise and finan-
cial resources of pharmaceutical companies without the 
necessity to seek a strategic investor and without the 
risk of losing control of their own drug candidates. Aca-
demic institutions such as UCSF, Harvard University or 
the University of Pennsylvania have realized the poten-
tial of long-term research alliances and have all formed 
partnerships with major research-based pharmaceutical 
companies such as Bayer, Sanofi, Boehringer Ingelheim 
or Novartis.
It is important to state that any kind of collaboration, 
alliance or partnership also creates a set of specific chal-
lenges. Among the latter are increased management 
complexity, coordination costs and the risk of IP failure. 
Academic research is often early-stage with respect to 
commercialization, and substantial additional work and 
financial investments are needed before a return-on-
investment can be expected. There is the constant chal-
lenge of early result publication since academia expects 
and needs findings to be published, while companies 
need to protect their assets via IP. These conflicts are not 
easy to solve and require tactful manoeuvring and mutual 
understanding of the different priorities.
Virtualization of R&D to increase efficiency
Virtual R&D pharmaceutical companies look to control 
overhead costs by operating a critical mass of internal 
expertise and complementing this with external know 
how and resources to drive internal R&D. In general, the 
fixed costs of R&D are reduced through the transfer of 
less intensively utilized services to partner companies, 
economies of scale and scope are leveraged, and flex-
ibility is increased by choosing the best R&D service 
providers globally [62–64]. This dynamic has four major 
advantages:
  • A reduction of internal complexity due to concentra-
tion,
  • A focus of resources on core technologies that may 
provide a competitive edge,
  • A mitigation of investment risks to partner compa-
nies, and
  • A reduction of external interfaces, since the task is 
now shared with the partner companies.
So far, virtual R&D has been successfully applied pre-
dominantly by SMEs, such as Fulcrum, Shire, Debiop-
harm or Endo Pharmaceuticals. Eli Lilly is an example 
of a global pharma company that also uses this open 
innovation model. It realized that the big pharma fran-
chise approach of a central R&D may not be applicable 
for all R&D projects. Thus, it established the Chorus 
group as a lean and efficient way to PoC that was bet-
ter suited to drug candidates that rely on targets with a 
lower target validation status and higher inherent tech-
nical risks. Chorus is a small and independent entity 
that has the goal to run clinical studies with a mini-
mum required data package in a “quick win, fast fail” 
model. It aims at advancing projects from candidate 
selection to PoC and to provide the candidates for Eli 
Lilly’s phase III pipeline [65]. It has the science-driven 
business model of a biotechnology company with flat 
hierarchies, fast decision-making processes and a pro-
ject organization as follows:
  • Projects have dedicated project-budgets,
  • The focus is on phase I and clinical PoC studies,
  • Projects are managed with small expert teams, and
  • The main tasks are run by intensive outsourcing.
By 2016, Chorus managed a portfolio of 15 drug pro-
jects with clinical trials in 19 countries with 40 full-time 
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equivalent staff. Chorus was able to run its operation 
with 25% of its budget as fixed overhead costs and 75% of 
the financial resources allocated to the external costs of 
the drug projects [65]. Overall, Eli Lilly’s concept of vir-
tual R&D met its proof-of-principle since its average suc-
cess rate in phase II improved significantly (54% Chorus 
vs. 29% traditional Eli Lilly) and its productivity increased 
by a factor of 3–10 compared with Eli Lilly’s traditional 
clinical development model [65].
Debiopharm is an additional example of the success 
of virtual R&D. It has been operating its business model 
successfully over the past 39  years by utilizing its inter-
nal expertise and absorptive capacities (60% of staff hold 
a Ph.D. or M.D.) in drug development to identify and in-
license promising therapies and develop them with the 
aim to outsource it to a partner with sales and market-
ing expertise. The company operates an open innovation 
model that engages external experts and service providers 
for project-related activities, with the flexibility to include 
vendors with the latest technologies and solutions to the 
question at hand. In consequence, Debiopharm has one 
of the highest revenue rates earned per employee across 
pharmaceutical companies, indicating the advantage of 
this open innovation model (see Table 4).
One of the core elements of the open innovator type 
“knowledge leverager” is the virtualization of R&D [4]. 
Shire is one of the prototypes of this model. Over the 
last 30  years, they have established themselves as one 
of the world’s fastest growing specialty pharma compa-
nies. Currently, they are one of the major players in rare 
diseases with a market capitalization of approximately 
USD 40 billion. Shire does not conduct any early internal 
research but chose to fill its portfolio through the acqui-
sition of companies with late phase assets that must be 
driven through the developmental process for approval 
and commercialization. Shire is a lean organization that 
is extremely cost effective, thus reflecting their high 
EBIT-margins, annual growth and flexibility with respect 
to changing environments and opportunities. Shire 
focuses its internal efforts around efficient clinical devel-
opment, fostering relationships with key opinion leaders 
and advocacy/patient groups around diseases of interest, 
and preparing the market (specifically around pricing 
and reimbursement).
Overall, the common denominator of these examples is 
a project-oriented organization of scientific and industry 
experts with excellent networks with industrial partners 
and academic institutions, a limited number of perma-
nent and costly headcounts and infrastructures, flexible 
access to external resources and knowledge on demand 
and an organizational structure that enables fast deci-
sion-making (Table 5).
Why is the potential of open innovation not fully 
utilized in the pharmaceutical industry yet?
During the past years, the industry has experimented 
with some collaborative R&D concepts that may help 
companies to open up their R&D towards external 
knowledge and technologies. Pharma innovation cen-
tres, research alliances, and the seeker-like approach in 
Table 4 The comparison of average revenue earned per employee across different pharmaceutical companies
NRDO ‘No Research, Development Only’ companies that do not conduct early research and have not chosen to conduct sell and market their own assets; + calculated 
over 6 years; ++ calculated over 7 years
Company Type Founded Number 
of employees
Average 10 years (2006–2016) 
revenue (M$)
Revenue 
per employee 
($)
Helsinn NRDO 1976 680 320 470,588
Jazz Pharma NRDO 2003 1040 615 591,346
Tesaro+ NRDO 2010 446 0.45 1010
Puma  Biotech++ NRDO 2010 183 0 0
Clovis NRDO 2009 278 0.14 504
Vanda Pharma NRDO 2002 148 38 256,756
Debiopharm NRDO 1979 150 345 2,300,000
Astra Zeneca Large Pharma 1999 59,700 23,000 385,260
Novartis Large Pharma 1996 12,3000 47,000 382,114
Sanofi Large Pharma 2004 110,000 32,500 295,454
Eli Lilly Large Pharma 1876 42,000 21,500 511,905
Bayer Large Pharma 1863 115,000 43,000 373,913
Pfizer Large Pharma 1849 96,500 51,000 528,497
GSK Large Pharma 2000 99,300 26,400 345,619
Amgen Large Biotech 1980 19,200 20,000 1,041,667
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active crowdsourcing are all open innovation concepts 
that are new for the industry, but that fit more with the 
traditional, predominantly internal R&D models of the 
big pharma companies. The industry also tested newer 
open innovation models, such as PPPs or open source, 
but primarily did so in research areas that do not affect 
its major franchises. Only Eli Lilly, Bayer Healthcare 
and some smaller players progressed in implement-
ing more open concepts, which is surprising in light 
of the enormous challenges that the industry is facing. 
Therefore, why has the industry not yet used the full 
potential of open innovation?
For example, implementing active crowdsourcing 
and running a proprietary crowdsourcing platform is 
related with challenges and requirements, such as
  • Company’s R&D processes need to be extroverted 
to implement external solutions,
  • R&D employees need to be open to ideas coming 
from the outside,
  • The R&D organization needs to have sufficient 
resources to access external innovation,
  • Internal champions need to be able to take the lead 
on external proposals,
  • An environment needs to exist that enables bilat-
eral agreements,
  • Concepts need to be in place regarding how to 
financially reimburse solvers properly and
  • Clear IP regulations need to be implemented that 
consider the needs of both parties.
In short, using the full potential of open innova-
tion would be linked to a change of the complete R&D 
model. Possible reasons for not completely embracing 
the full potential of open innovation could be related 
to the factors of (1) legacy, (2) risk, and (3) control.
Legacy
1. Changing cultures: Shifting an R&D organization’s 
traditional R&D model to a new one could be viewed 
as an unnecessary attempt since the old R&D strat-
egy is often hard-wired in the DNA of the organiza-
tion and the culture of its people.
2. Changing people: The typical pharma scientist in the 
big pharma franchise model still tends to be a more 
introverted specialist, whereas working in an envi-
ronment of external collaboration or virtual R&D 
requires individuals to be drug developers with excel-
lent communicative and collaborative skills and net-
works that they bring to the project teams.
Risk
1. Risk associated with academic research: Drug devel-
opment is certainly more costly and challenging 
today than in the past. The expectation to deliver dif-
ferentiated products in stratified populations in exist-
ing markets increases the bar for success. There is no 
doubt that academic institutions and biotech groups 
are conducting innovative research in certain disease 
areas and generating new targets in new indications. 
However, a great deal of these targets are not clini-
cally validated.
2. Return-on-investment risk of licensing: Recent deals 
seem to suggest that for relatively early projects, the 
market is willing to pay several multiples of the value 
of an asset, thus making the internal generation of 
assets more attractive again.
3. Financial risk of restructuring: The costs for restruc-
turing a global R&D group located at different sites 
to become a slim virtual organization and the effort 
involved in changing the mindset and culture would 
be substantial.
Table 5 Success factors of virtual R&D
Advantages of a virtual R&D organization Essential elements to operate a virtual R&D organization
Instant access to new technologies and external resources on demand Excellent industry and academic networks
Reduced capital requirements (overhead and infrastructure) Professional, project, portfolio and alliance management skills
Simple governance structure Simple governance structure
Reduced bureaucracy and faster decision making Collaborative scientific and medical support from those who 
understand drug development
Flexibility in selecting optimal services providers Excellent expertise in risk management and financial valuation
Mitigated financial risk Outperforming licensing and acquisition strategies and skills
Reduced time to market Admirable outsourcing skills
Excellent communication and motivation skills to manage 
external project teams
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Control
1. Controlling IP: External innovation and IP often 
tend to result in multiple contributors where each 
requires a percentage of the royalties and an unrealis-
tic upfront payments and milestones.
2. Controlling markets and competitors: Although big 
pharma has moved to a leaner and more focused 
R&D model for non-core assets, they have been 
reluctant to apply a similar model to their core assets. 
These major franchises have been established over 
the years in specific therapeutic areas where a large 
amount of investments has been realized in infra-
structure, established knowledge and expertise, 
which they are reluctant to dismantle since it pro-
vides a competitive edge.
For example, the difficulties associated with the 
change of the R&D model and culture can in retrospect 
be exemplified by the ALTANA-Nycomed–Takeda 
mergers. In 2006, the Danish Nycomed AS bought the 
German ALTANA AG. Nycomed came along with a 
team of approximately 100 full time equivalents who 
have been working according to the “knowledge integra-
tor” approach, whereas ALTANA’s tenfold larger R&D 
organization traditionally had been operating according 
to the “knowledge creator” model. Nycomed’s intention 
was to run the newly generated joint R&D organization 
according to the open innovator of a “knowledge lever-
ager” and therefore make the organization more extro-
verted than ALTANA traditionally was. Although there 
were many isolated project successes, the attempt to 
shift the R&D model and employ more open innovation 
concepts was ultimately not embraced on a broad basis 
and was eventually abandoned when Nycomed was 
sold to Takeda in 2012. The goal to establish a “knowl-
edge leverager” model was driven by the head of R&D 
and the next two management levels, but it was never 
fully supported by other C-suite leaders whose focuses 
were to defend their organizations, structures and 
approaches. The more traditional knowledge creator 
model of ALTANA acted as a brake for the execution of 
the new open innovator by focusing too intensively on 
internal innovation and maximizing the value of late-
stage assets. The predominant organizational R&D cul-
ture also limited the influence of the open innovation 
strategy implementation. R&D employees were often 
distrustful of any replacement of internal capacities by 
external resources, in-house scientists were sceptical of 
any external asset to be evaluated for licensing (“not-
invented-here”) and R&D managers were too anchored 
in the competitive mode to understand how to build a 
culture of collaboration and creative working with mul-
tiple partners and stakeholders.
To conclude, the influence of the more traditional 
organizational culture should have been reduced by:
  • Challenging the automatic distrust towards external 
partners who are motivated differently,
  • Questioning the over-identification with inter-
nal capabilities and thereby overcoming the “not-
invented-here syndrome”,
  • Letting go of the limiting competitive reactiveness 
that sees everyone outside of the organization as a 
potential threat, and
  • Reducing the influence of control in decision making.
Changing an R&D model involves cultural change. 
Thus, this change takes time and is a huge effort. A McK-
insey survey of 3199 executives around the world found 
that only one out of every three transformations succeeds 
[66]. This low success rate prompts the question of how 
pharma can increase its chances of success, for example, 
when changing its R&D model to the open innovator of 
a “knowledge leverager” and copy the successful biotech 
business model that continuously outperformed large 
pharma with respect to their R&D output [67]. Possible 
answers include:
  • Incubate a new project that is geographically and 
structurally separate and protect it from the rest of 
the organization. If the project grows and succeeds, 
gradually redirect investment funds towards it and 
away from traditional operations.
  • Recruit an elite team from within the old organiza-
tion and from outside along with the downsizing or 
closure of the existing operations.
  • Establish a company-based R&D-independent fund 
that supports new innovative ideas from employees. 
These can be projects that either do not have a home 
in a functional line or therapeutic area or that are 
(currently) regarded as out of scope.
In any case, any new concept to open up pharma R&D 
needs to be linked to a new and more entrepreneurial 
organizational culture and an open and collaborative 
mindset of the people. The challenge for the more con-
servative large pharma companies in general is to main-
tain the entrepreneurial spirit at a large scale, which 
must also involve innovative approaches to legacy, risk 
and control. Some large pharma (e.g., Eli Lilly, GSK or 
J&J) have experimented with smaller, more autono-
mous units, or even new R&D models (e.g., Nycomed), 
but may have ignored the underlying influence of the 
old R&D model, thus leading to mixed results. Eli Lilly 
has been very successful with Chorus. G4T is another 
positive example of how an open innovation model can 
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be implemented. In addition, Actelion can also be seen 
as a successful example and representative since inno-
vation and entrepreneurial spirit is their motor, as they 
continuously kept investing in its R&D, even in case of 
drawbacks. The fact that even after having sold Acte-
lion to J&J for USD 30 billion the “Idorsia” (the R&D 
part of Actelion) was not part of the deal (and will 
remain operational and independent) underscores that 
R&D can be both very profitable and successful if well 
managed [68].
What can big pharma learn from the new open 
innovator types?
Companies following a more traditional R&D Model 
(such as the open innovator “knowledge creator”) have 
a fundamentally different view of R&D than those 
companies that operate a completely open R&D con-
cept. The open innovator of a “knowledge creator” is 
based on a predominantly internally generated R&D 
pipeline with a preference for introverted innovation 
management [4] that is based on highly innovative 
research approaches, the assessment of medical needs 
(to address real needs) and the understanding of basic 
biological principles (work on the right targets and thus 
reduce technical risks). In contrast, companies with a 
virtual R&D model are innovative in their business 
models (i.e., with respect to scouting, business devel-
opment and licensing activities) rather than in their 
research approaches.
Therefore, what can the more traditional big pharma 
companies learn from this more open R&D model?
1. Expand the portfolio strategy: Re-position projects 
that would have been put on hold or out-licensed. 
Since the true commercial value of an asset is often 
difficult to assess, decisions should be made based on 
their transformative potential rather than sales pre-
dictions.
2. Reduce costs: Big pharma companies need to focus 
more on project-related expenditures rather than on 
capacity or capability building. With today’s rapidly 
changing environment, they often can be insourced 
and might be outdated once they are built internally.
3. Increase flexibility: This relates to a mindset that 
implies that a discovery that might not fit the cor-
porate goals or project portfolio still can be of high 
value or impact to another part of the organization or 
therapeutic area. Assumed or perceived R&D strat-
egies with seemingly defined out-of-scope areas can 
limit employees’ creativity and ownership. Thus, con-
sidering opportunities should become a part of big 
pharma’s mindset.
Conclusions
Currently, pharmaceutical companies can benefit from 
numerous sources of external innovation, including open 
sourcing, crowdsourcing, public private partnerships, 
dedicated innovation centres and research alliances. To 
this end, pharmaceutical companies need to develop 
absorptive capacities where external knowledge gets 
identified, valuated and actively incorporated. To release 
the next wave of innovation in the pharmaceutical indus-
try, pharma companies need to tap external sources of 
innovation. However, first they need to be innovative in 
the way that they design new organizations that are fit for 
external innovation. Depending on the companies’ sizes, 
their portfolio breadths and their strategic goals, com-
panies need to apply different open innovation models 
ranging from simply adding elements of open innovation 
to their existing R&D models to completely virtualizing 
their R&D. The available options are pretty different from 
each other and have specific advantages and shortcom-
ings. A best-in-class or ones-size-fits-all approach can-
not be recommended currently. Instead, drug innovators 
need to choose the option that best fits their current 
needs and strategic directions. Companies aiming at lev-
eraging the full potential of open innovation first need to 
adapt their approaches with respect to the three success 
factors, namely, legacy, risk and control. Second, they 
need to fully engage their external partners and resources 
in a truly collaborative model, which provides benefits to 
all partners involved.
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